Patents by Inventor Robert Anholt

Robert Anholt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12773407
    Abstract: This disclosure relates to using compounds disclosed herein to treat or prevent cocaine use disorder, cocaine toxicity, or other drug related disorders. In certain embodiments, this disclosure relates to methods of treating drug addiction or to help prevent relapse. In certain embodiments, this disclosure relates to methods of treating or preventing cocaine use disorder, cocaine toxicity, or other use disorders comprising administering an effective amount of a compound disclosed herein, such as ibrutinib, [(R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one], derivative, or salt thereof to a subject in need thereof. In certain embodiments, the compound is a Bruton's tyrosine kinase (BTK) inhibitor.
    Type: Grant
    Filed: August 30, 2021
    Date of Patent: October 27, 2026
    Assignees: Emory University, Clemson University Research Foundation
    Inventors: Spencer B. Huggett, Rohan H. C. Palmer, Robert Anholt, Trudy MacKay
  • Publication number: 20240024325
    Abstract: This disclosure relates to using compounds disclosed herein to treat or prevent cocaine use disorder, cocaine toxicity, or other drug related disorders. In certain embodiments, this disclosure relates to methods of treating drug addiction or to help prevent relapse. In certain embodiments, this disclosure relates to methods of treating or preventing cocaine use disorder, cocaine toxicity, or other use disorders comprising administering an effective amount of a compound disclosed herein, such as ibrutinib, [(R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one], derivative, or salt thereof to a subject in need thereof. In certain embodiments, the compound is a Bruton's tyrosine kinase (BTK) inhibitor.
    Type: Application
    Filed: August 30, 2021
    Publication date: January 25, 2024
    Inventors: Spencer B. Huggett, Rohan H. C. Palmer, Robert Anholt, Trudy MacKay